


RESEARCH ANTIBODY MARKET ANALYSIS:

Reviewing 2023 Performance
and Projecting Future Trends



Guiding Strategic Growth...

PIVOTAL
SCIENTIFIC

Research use only (RUO) antibody market worth \$7,155 million by 2030

This report will provide readers with:


- 90 pages of meticulously researched insights
- Insight into the key drivers and restraints influencing market growth
- Identification of opportunities and critical assessment of the competitive landscape
- Sharing latest technological developments and corporate growth strategies
- Forward-looking perspective from 2024 onwards
- Trends and reflections on M&A activities 2022/2023 with forward prediction to 2024

Allowing readers to:


- Effectively navigate and understand the intricacies of the RUO antibody market
- Inform strategic decision making
- Empower growth and success for their businesses
- Unlock opportunities and routes for expansion, both organic and inorganic
- Assess the market opportunity from an acquisition perspective

Pivotal Scientific Limited's 'Research Antibody Market Analysis' projects that market size will reach \$7,155m by 2030, from a base line of \$X,XXX in 2022, growing at a CAGR of 7.46%. The growth of the market continues to be driven by ongoing demand for reproducible research, global drive to bolster R&D into existing and emerging health conditions, growing interest in antibody discovery and technological advancements fuelled by increased public and private investment.


Research Use Only (RUO) Antibody Market Size (USD Million), 2022 - 2030



Research Design Summary



The RUO antibody market has, in recent years, continued to shift away from the growth and dynamics of the COVID pandemic. Overall, the market has sustained a period of readjustment in the wake of the pandemic, with the super-charged growth rates seen mid-pandemic easing to a slower 7.46% CAGR. Despite this step down, the market has continued to grow with the adaptability of the industry, a quality highlighted on a global scale during the pandemic, driving continued strong growth. 2023 saw a recalibration of the market amidst global economic headwinds, shifting therapeutic foci and ever-changing priorities. As we look ahead into 2024, monitoring the market, and its dynamics, will be key in assessing windows of opportunity for commercial entities. This market analysis provides readers with a nuanced understanding of these opportunities, and the state of the current market, to support and inform forward growth of both the market and our readers' businesses.



Some of the prominent key players discussed in this analysis are:

- Abcam (USA)
- Thermo Fisher Scientific (USA)
- Merck KGaA (Germany)
- Bio-Techne (USA)
- Becton Dickinson (USA)
- Bio-Rad Laboratories (USA)
- Proteintech (USA)
- Cell Signaling Technology (USA)
- Absolute Biotech (USA)

Browse an expert interpretation of the RUO antibody market across 90+ pages on:

- Market Definition & Characteristics
- Market Size Estimation
- Growth Rate Estimation
- Market size 2022-2030
- Market Dynamics
- Drivers
- Opportunities
- Challenges
- Restraints

Market Analysis by

- Antibody type
- Production
- Purchasing and Supply
- Routes to market – bulk, custom, OEM, licensing, distribution

Purchasing Behaviour

Mergers and Acquisitions (M&A) Activity

- Key acquisitions in 2022/23
- M&A strategies in 2022/23
- Challenges to M&A Deals
- Multiples trends in 2022/2023
- Future projections

Industry Trends

- Validation
- Recombinant Antibodies
- Personalised Medicine & Precision Medicine
- Multiplexing
- Spatial Omics
- Infectious Disease
- Oncology
- AI

Competitive landscapes of key players

This Report on the Research Antibody Market is provided to you on the basis that you shall not publish or disclose to any third party any of the information outlined unless specifically authorised to do so by Pivotal Scientific or by law or the rules of any competent regulated authority.

You agree that this report is given to you on the basis that it may not be disclosed to, used or relied on by, any other 3rd person or Company without the prior written permission from Pivotal Scientific.

You irrevocably agree to indemnify and hold harmless the Pivotal Group and its directors, officers, employees, controlling persons, associates, consultants, affiliates and agents to the full extent lawful against all and any indemnified losses as a result of any information/advice provided to you within this Antibody Report.

Pricing:

General per organisation cost:

£4,500

PSL Alliance members receive

25% discount